CAMBRIDGE, MA., – January 5, 2023 – HiFiBiO Therapeutics CEO Liang Schweizer spoke with Don Davis on the Life Science Success Podcast about her professional journey and how HiFiBiO is using its single-cell driven Drug Intelligence Science (DISTM) platform to accelerate the delivery of precision immunotherapies to patients.
Link to the podcast here!
About HiFiBiO Therapeutics
HiFiBiO Therapeutics is a clinical stage biotech company advancing a robust pipeline targeting both the innate and adaptive immunity to treat cancer and autoimmune diseases. Its proprietary and versatile DIS™ single-cell platform enables the rapid discovery of novel antibody therapeutics with predictive biomarkers through our internal development programs and strategic collaborations. Our passionate team across three continents embraces a fast-paced and engaging work environment to bring transformative medicines to patients. www.hifibio.com
HiFiBiO Therapeutics, HiFiBiO Therapeutics logo, and DIS are trademarks of HiFiBiO and its affiliates.